Horizon Therapeutics PLC (NASDAQ:HZNP)

110.63
Delayed Data
As of Jan 27
 -0.62 / -0.56%
Today’s Change
57.84
Today|||52-Week Range
117.49
-2.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$25.7B

Company Description

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Contact Information

Horizon Therapeutics Plc
70 St. Stephen's Green
Dublin Dublin 4
P:(531) 772-2100
Investor Relations:

Employees

Shareholders

Other institutional54.51%
Mutual fund holders49.54%
Individual stakeholders1.07%

Top Executives

Timothy P. WalbertChairman, President & Chief Executive Officer
Aaron L. CoxChief Financial Officer & Executive Vice President
Jeffrey W. ShermanChief Medical Officer & Executive Vice President
Jeffrey D. KentExecutive VP-Medical Affairs & Outcomes Research
Michael A. DesJardinExecutive VP-Technical Operations & Quality